Literature DB >> 16185313

The effects of tegaserod, a 5-HT receptor agonist, on gastric emptying in a murine model of diabetes mellitus.

M D Crowell1, C Mathis, V A Schettler, T Yunus, B E Lacy.   

Abstract

UNLABELLED: The C57BLKS/J db/db transgenic mouse is a model of diabetes mellitus that has been shown to have delayed gastric emptying. We assessed gastric emptying rates in C57BLKS/J mice, and determined the effects of tegaserod, a new selective 5-HT(4) receptor partial agonist, on gastric emptying.
METHODS: Gastric emptying rates of a 20% glucose test meal were determined in 12-20-week-old female db/db mice and control littermates. The effects of tegaserod (0.1-2.0 mg kg(-1), i.p.) on gastric transit were tested in a second group of db/db mice. Pretreatment with GR11308, a specific 5-HT(4)antagonist, was used to confirm the mechanism of action of tegaserod on gastric emptying.
RESULTS: Gastric emptying of glucose was significantly slower in db/db mice than in control littermates. Tegaserod (0.1 mg kg(-1)) significantly accelerated the gastric emptying rate of glucose in db/db mice, reducing the fraction of the meal remaining in the stomach at 30 min by 80%. GR11308 blocked the gastrokinetic effects of tegaserod.
CONCLUSIONS: Gastric emptying was impaired in db/db mice. Low dose tegaserod improved gastric emptying rates in this model of gastroparesis through the activation of 5-HT(4) receptors. These findings suggest that 5-HT(4) receptor agonists may prove useful for improving delayed gastric emptying in gastroparesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16185313     DOI: 10.1111/j.1365-2982.2005.00681.x

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  6 in total

1.  The effect of tegaserod on esophageal submucosal glands bicarbonate and mucin secretion.

Authors:  Solange Abdulnour-Nakhoul; Nelia A Tobey; Nazih L Nakhoul; Scott A Wheeler; Ximena Vanegas; Roy C Orlando
Journal:  Dig Dis Sci       Date:  2008-02-13       Impact factor: 3.199

Review 2.  Pathophysiology and management of diabetic gastropathy: a guide for endocrinologists.

Authors:  Paul Kuo; Christopher K Rayner; Karen L Jones; Michael Horowitz
Journal:  Drugs       Date:  2007       Impact factor: 9.546

3.  The tryptophan hydroxylase inhibitor LX1031 shows clinical benefit in patients with nonconstipating irritable bowel syndrome.

Authors:  Philip M Brown; Douglas A Drossman; Alastair J J Wood; Gary A Cline; Kenny S Frazier; Jessica I Jackson; Johanna Bronner; Joel Freiman; Brian Zambrowicz; Arthur Sands; Michael D Gershon
Journal:  Gastroenterology       Date:  2011-05-18       Impact factor: 22.682

4.  Physiological modulation of intestinal motility by enteric dopaminergic neurons and the D2 receptor: analysis of dopamine receptor expression, location, development, and function in wild-type and knock-out mice.

Authors:  Zhi Shan Li; Claudia Schmauss; Abigail Cuenca; Elyanne Ratcliffe; Michael D Gershon
Journal:  J Neurosci       Date:  2006-03-08       Impact factor: 6.167

5.  Modifying ligand-induced and constitutive signaling of the human 5-HT4 receptor.

Authors:  Wei Chun Chang; Jennifer K Ng; Trieu Nguyen; Lucie Pellissier; Sylvie Claeysen; Edward C Hsiao; Bruce R Conklin
Journal:  PLoS One       Date:  2007-12-19       Impact factor: 3.240

Review 6.  Gastroparesis Updates on Pathogenesis and Management.

Authors:  Nanlong Liu; Thomas Abell
Journal:  Gut Liver       Date:  2017-09-15       Impact factor: 4.519

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.